ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Good overall result and revenue growth for the ZEISS Group

By: PR Leap
(PRLeap.com) ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) - EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.

  • Increasingly challenging market environment for the direct-to-market segments

  • Strong growth in the Semiconductor Manufacturing Technology segment

  • Outlook requires reinforcement of resilience measures


  • Overall, ZEISS can look back on a very successful fiscal year 2023/24. The Group's revenue rose to 10.894 billion euros (prior year: 10.108 billion euros, up 8%). Earnings before interest and taxes (EBIT) totaled 1.444 billion euros (prior year: 1.686 billion euros) with an EBIT margin of 13%. All four segments of the ZEISS Group contributed to this growth. The challenges posed by geopolitical tensions and the current weaker global economic situation have, however, intensified and impacted the segments to varying degrees.

    "Overall, we ended fiscal year 2023/24 with a good result and revenue growth. At the same time, it was not possible for all areas to escape the impact of current developments on the global markets," said Dr. Karl Lamprecht, President and CEO of ZEISS. "Our success is based on our enormous innovative strength. To make sure it stays that way, we have spent a record 15% of revenue on research and development - and thus more than ever before - and also invested in the targeted expansion of personnel and infrastructure."

    Segment development
    Revenue (in million euros)
    2023/24 2022/23 Change (adjusted for
    currency effects)

    Semiconductor Manufacturing Technology 4,122 3,555 16% (16%)
    Industrial Quality & Research 2,369 2,295 3% (5%)
    Medical Technology* 2,611 2,504 4% (7%)
    Consumer Markets 1,666 1,624 3% (4%)

    * Not identical to the Carl Zeiss Meditec Group                                                                                 

    GET IN TOUCH
    J�rg Nitschke
    ZEISS Group
    +49 7364 20-3242
    http://www.zeiss.com/newsroom

    You can see the original version and more on PRLeap here: http://www.prleap.com/pr/301688/good-overall-result-and-revenue-growth-for-the-zeiss-group

    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.


     

    IntelligentValue Home
    Close Window

    DISCLAIMER

    All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

    Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.